Product Document Searching Made Easy by 2D Code! | TCI Chemistry News June 2026 | [TCIPracticalExample] Oxidation Reaction of Heterocycles Using... | Various analytical charts can be searched on each product detail page and Product Document Search (The kinds of analytical charts differ by product)
Maximum quantity allowed is 999
Please select the quantity
CAS RN: 29767-20-2 | Product Number: T3109
Teniposide
×
Purity: >98.0%(HPLC)
Synonyms:
Product Documents:
| Size | Unit Price | Same Day | 2-3 Business Days | Other Lead Time |
Shipping Information
|
|---|---|---|---|---|---|
| 20MG |
$56.00
|
7 | ≥40 | Contact Us | |
| 100MG |
$194.00
|
9 | 4 | Contact Us |
* Please contact our distributors or
TCI
to order our products. The above prices do not include freight cost, customs, and other charges to the destination.
* The storage conditions are subject to change without notice.
| Product Number | T3109 |
Purity / Analysis Method 
|
>98.0%(HPLC) |
| Molecular Formula / Molecular Weight | C__3__2H__3__2O__1__3S = 656.66 |
| Physical State (20 deg.C) | Solid |
| Storage Temperature
|
Frozen (-20°C) |
| Condition to Avoid | Heat Sensitive |
| Packaging and Container
|
100MG-Glass Bottle with Plastic Insert (View image), 20MG-Glass Bottle with Plastic Insert (View image) |
| CAS RN | 29767-20-2 |
| Reaxys Registry Number | 7108452 |
| PubChem Substance ID | 253662241 |
| Merck Index (14) | 9145 |
| MDL Number | MFCD00866516 |
Specifications
| Appearance | White to Almost white powder to crystaline |
| Purity(HPLC) | min. 98.0 area% |
| Specific rotation [a]20/D | -107.0 to -115.0 deg(C=1, CHCl3:MeOH=9:1) |
Properties (reference)
| Melting Point | 247 °C(dec.) |
| Specific Rotation | -111° (C=1,CHCl3:MeOH=9:1) |
| Maximum Absorption Wavelength | 283 nm (MeOH) |
| Solubility in water | Insoluble |
| Degree of solubility in water | 5.9 mg/l 25 °C |
GHS
| Pictogram |
|
| Signal Word | Danger |
| Hazard Statements | H361 : Suspected of damaging fertility or the unborn child. H371 : May cause damage to organs. H372 : Causes damage to organs through prolonged or repeated exposure. H341 : Suspected of causing genetic defects. H350 : May cause cancer. |
| Precautionary Statements | P501 : Dispose of contents/ container to an approved waste disposal plant. P260 : Do not breathe dust. P270 : Do not eat, drink or smoke when using this product. P202 : Do not handle until all safety precautions have been read and understood. P201 : Obtain special instructions before use. P264 : Wash skin thoroughly after handling. P280 : Wear protective gloves/ protective clothing/ eye protection/ face protection. P308 + P311 : IF exposed or concerned: Call a POISON CENTER/doctor. P405 : Store locked up. |
Related Laws:
| RTECS# | KC0180000 |
Transport Information:
| H.S.code* | 2938.90-000 |
Application
Adeno-associated virus vector transduction enhancer
Teniposide exhibits enhancement of adeno-associated virus transduction.1)
References
- 1) Identification and validation of small molecules that enhance recombinant adeno-associated virus transduction following high-throughput screens
Application
Teniposide: An Inhibitor of Topoisomerase II
Teniposide (VM26) and etoposide (VP16-213) [E0675] are semisynthetic derivatives of podophyllotoxin [P1771], an alkaloid. Teniposide and teniposide are an inhibitor of topoisomerase II such as doxorubicin [D4193], daunorubicin [D4532]. Topoisomerase II is an enzyme essential for DNA replication, chromosome condensation and chromosome segregation. Topoisomerase II inhibitors are potent inducers of double strand breaks in DNA, and can cause arrest in the cell cycle at the G2 stage. Therefore, topoisomerase II inhibitors are the most widely used anti-cancer agents. Teniposide is used for the treatment of acute lymphocytic leukemia (ALL). (The product is for research purpose only.)
References
- The podophyllotoxin derivatives VP16-213 and VM26 (a review)
- The clinical pharmacology of etoposide and teniposide (a review)
- Clinical applications of anticancer drugs targeted to topoisomerase II
- Podophyllotoxin (a review)
- Podophyllotoxin derivatives: current synthetic approaches for new anticancer agents
PubMed Literature
Documents
Product Articles
Product Documents (Note: Some products will not have analytical charts available.)
Enter TCI Product Number
Enter KISHIDA Product Number
4-5 alphanumeric characters before the hyphen
7 alphanumeric characters
Safety Data Sheet (SDS)
Please select Language.
The requested SDS is not available.
Please Contact Us for more information.
• The requested SDS is not available.
Specifications
The requested specifications are not available.
Please Contact Us for more information.
The requested specifications are not available.
C of A & Other Certificates
Please enter Lot Number
Incorrect Lot Number. Please input only the 4-5 alphanumeric characters before the hyphen.
Incorrect Lot Number. Please input only the 7 alphanumeric characters.
• Please check that the lot number you have entered is correct. It is 4-5 alphanumeric characters before the hyphen. In particular, please check O (letter) or 0 (number) and I (letter) or 1 (number).
• If your information is correct and you are still not able to view the requested certificates, Please Contact Us for more information.
• Please check that the lot number you have entered is correct. It is 7 alphanumeric characters. In particular, please check O (letter) or 0 (number) and I (letter) or 1 (number).
Sample C of A
This is a sample C of A and may not represent a recently manufactured lot of the product.
A sample C of A for this product is not available at this time.
Analytical Charts
Please enter Lot Number
Incorrect Lot Number. Please input only the 4-5 alphanumeric characters before the hyphen.
Incorrect Lot Number. Please input only the 7 alphanumeric characters.
The requested analytical chart is not available. Sorry for the inconvenience.